mRNA-based Detection of Rare CFTR Mutations Improves Genetic Diagnosis of Cystic Fibrosis in Populations with High Genetic Heterogeneity

Abstract

Even with advent of Next Generation Sequencing complete sequencing of large disease-associated genes and intronic regions is economically not feasible. This is the case of CFTR, the gene responsible for Cystic Fibrosis (CF). Yet, to confirm a CF diagnosis, proof of CFTR dysfunction needs to be obtained, namely by identification of two disease-causing mutations. Moreover, with the advent of mutation-based therapies, genotyping is an essential tool for CF disease management. There is however, still an unmet need to genotype CF patients by fast, comprehensive and cost-effective approaches, especially in populations with high genetic heterogeneity (and low p.F508del incidence), where CF is now emerging with new diagnosis dilemmas (Brazil, Asia, etc).

Herein, we report an innovative mRNA-based approach to identify CFTR mutations in the complete coding and intronic regions. We applied this protocol to genotype individuals with a suspicion of CF and only 1/no CFTR mutations identified by routine methods. It successfully detected multiple intronic mutations unlikely to be detected by CFTR exon sequencing.

We conclude that this is a rapid, robust and inexpensive method to detect any CFTR coding/ intronic mutation (including rare ones) that can be easily used either as primary approach or after routine DNA analysis.

from Genetics via xlomafota13 on Inoreader http://ift.tt/1s5eQaz
via IFTTT